Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. We are commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TUKYSA®, or tucatinib, for the treatment of certain metastatic HER2-positive breast and colorectal cancers, and TIVDAK®, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. We are also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Many of our programs, including ADCETRIS, PADCEV and TIVDAK, are based on our ADC technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
Company profile
Ticker
SGEN
Exchange
Website
CEO
Clay B. Siegall
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SEATTLE GENETICS INC /WA
SEC CIK
Corporate docs
Subsidiaries
East Coast Ventures, Inc. • Seagen Australia Pty Limited • Seagen Austria GmbH • Seagen B.V. • Seagen Canada Inc. • Seagen Denmark ApS • Seagen France SAS • Seagen Germany GmbH • Seagen International GmbH • SeaGen International Holdings, LLC ...
IRS number
911874389
SGEN stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
26 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Dec 23
Transcripts
SGEN
Earnings call transcript
2022 Q4
15 Feb 23
SGEN
Earnings call transcript
2022 Q3
28 Oct 22
SGEN
Earnings call transcript
2022 Q2
29 Jul 22
SGEN
Earnings call transcript
2022 Q1
28 Apr 22
SGEN
Earnings call transcript
2021 Q4
10 Feb 22
SGEN
Earnings call transcript
2021 Q3
29 Oct 21
SGEN
Earnings call transcript
2021 Q2
30 Jul 21
SGEN
Earnings call transcript
2021 Q1
1 May 21
SGEN
Earnings call transcript
2021 Q1
29 Apr 21
SGEN
Earnings call transcript
2020 Q4
12 Feb 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 429.16 mm | 429.16 mm | 429.16 mm | 429.16 mm | 429.16 mm | 429.16 mm |
Cash burn (monthly) | (no burn) | (no burn) | 77.11 mm | 65.88 mm | 11.94 mm | 45.01 mm |
Cash used (since last report) | n/a | n/a | 587.44 mm | 501.88 mm | 90.97 mm | 342.90 mm |
Cash remaining | n/a | n/a | -158.28 mm | -72.72 mm | 338.19 mm | 86.26 mm |
Runway (months of cash) | n/a | n/a | -2.1 | -1.1 | 28.3 | 1.9 |
Institutional ownership, Q3 2023
84.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 600 |
Opened positions | 84 |
Closed positions | 58 |
Increased positions | 232 |
Reduced positions | 176 |
13F shares | Current |
---|---|
Total value | 33.61 tn |
Total shares | 158.60 mm |
Total puts | 32.36 mm |
Total calls | 8.19 mm |
Total put/call ratio | 4.0 |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 44.55 mm | $9.45 tn |
Vanguard | 13.32 mm | $2.83 tn |
Pentwater Capital Management | 12.88 mm | $2.73 tn |
BLK Blackrock | 12.05 mm | $2.56 tn |
Primecap Management | 6.26 mm | $1.33 tn |
STT State Street | 3.36 mm | $712.70 bn |
Millennium Management | 3.07 mm | $650.39 bn |
Citadel Advisors | 2.43 mm | $515.19 bn |
Capital World Investors | 2.36 mm | $500.61 bn |
Balyasny Asset Management | 2.28 mm | $483.42 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Dec 23 | Charles R Romp | Common Stock | Sale back to company | Dispose D | No | No | 229 | 33,796 | 7.74 mm | 0 |
14 Dec 23 | Charles R Romp | Performance Stock Units Common stock | Sale back to company | Dispose D | No | No | 0 | 2,912 | 0.00 | 0 |
14 Dec 23 | Charles R Romp | Performance Stock Units Common stock | Sale back to company | Dispose D | No | No | 0 | 1,165 | 0.00 | 0 |
14 Dec 23 | Charles R Romp | Performance Stock Units Common stock | Sale back to company | Dispose D | No | No | 0 | 1,044 | 0.00 | 0 |
14 Dec 23 | Charles R Romp | Performance Stock Units Common stock | Sale back to company | Dispose D | No | No | 0 | 874 | 0.00 | 0 |
14 Dec 23 | Charles R Romp | Performance Stock Units Common stock | Sale back to company | Dispose D | No | No | 0 | 1,457 | 0.00 | 0 |
14 Dec 23 | Charles R Romp | Performance Stock Units Common stock | Sale back to company | Dispose D | No | No | 0 | 12,688 | 0.00 | 0 |
14 Dec 23 | Charles R Romp | Performance Stock Units Common stock | Sale back to company | Dispose D | No | No | 0 | 9,883 | 0.00 | 0 |
14 Dec 23 | Charles R Romp | Performance Stock Units Common stock | Sale back to company | Dispose D | No | No | 0 | 6,017 | 0.00 | 0 |
14 Dec 23 | Charles R Romp | Performance Stock Units Common stock | Sale back to company | Dispose D | No | No | 0 | 583 | 0.00 | 0 |